A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer

被引：0
|
作者：
Kaisa Leea Sunela
Sanna Koskinen
Pirkko-Liisa Kellokumpu-Lehtinen
机构：
[1] Tampere University Hospital,Department of Oncology
[2] University of Tampere Medical School,Department of Oncology
[3] University of Tampere,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2010年 / 66卷
关键词：
Renal cell carcinoma; Immunotherapy; Interferon; Pegylated; Chemotherapy; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：59 / 67
页数：8
相关论文
共 50 条
  • [1] A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer
    Sunela, Kaisa Leea
    Koskinen, Sanna
    Kellokumpu-Lehtinen, Pirkko-Liisa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 59 - 67
  • [2] Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study
    Padrik, P
    Leppik, K
    Arak, A
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (05) : 387 - 392
  • [3] PHASE-II STUDY OF INTERFERON ALFA-2A AND DACARBAZINE IN ADVANCED MELANOMA
    BAJETTA, E
    DILEO, A
    ZAMPINO, MG
    GIANNOTTI, B
    BROGELLI, L
    ARDIZZONI, A
    SERTOLI, MR
    BERNENGO, MG
    BARDUAGNI, M
    MAIFREDI, G
    ZUMIANI, G
    COMELLA, G
    BUZZONI, R
    ZILEMBO, N
    CRISCUOLO, D
    MASSIMINI, G
    CASCINELLI, N
    EUROPEAN JOURNAL OF CANCER, 1992, 28A (10) : 1719 - 1720
  • [4] PHASE-II STUDY OF INTERFERON ALFA-2A, RECOMBINANT (ROFERON-A) IN METASTATIC RENAL-CELL CARCINOMA
    BUZAID, AC
    ROBERTONE, A
    KISALA, C
    SALMON, SE
    JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (07) : 1083 - 1089
  • [5] PHASE-II STUDY OF RECOMBINANT ALFA-2A INTERFERON IN PATIENTS WITH ADVANCED BONE SARCOMAS
    EDMONSON, JH
    LONG, HJ
    FRYTAK, S
    SMITHSON, WA
    ITRI, LM
    CANCER TREATMENT REPORTS, 1987, 71 (7-8): : 747 - 748
  • [6] PHASE-II STUDY OF FLUOROURACIL, LEUCOVORIN, AND INTERFERON ALFA-2A IN METASTATIC COLORECTAL-CARCINOMA
    GREM, JL
    JORDAN, E
    ROBSON, ME
    BINDER, RA
    HAMILTON, JM
    STEINBERG, SM
    ARBUCK, SG
    BEVERIDGE, RA
    KALES, AN
    MILLER, JA
    WEISS, RB
    MCATEE, N
    CHEN, A
    GOLDSPIEL, B
    SOVER, E
    ALLEGRA, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (09) : 1737 - 1745
  • [7] A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor
    Axel Bex
    Henk Mallo
    Martijn Kerst
    John Haanen
    Simon Horenblas
    Gijsbert C. de Gast
    Cancer Immunology, Immunotherapy, 2005, 54 : 713 - 719
  • [8] A phase-II study of pegylated interferon alfa-2b for patients with metastatic renal cell carcinoma and removal of the primary tumor
    Bex, A
    Mallo, H
    Kerst, M
    Haanen, J
    Horenblas, S
    de Gast, GC
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2005, 54 (07) : 713 - 719
  • [9] PHASE-II TRIAL OF ISOTRETINOIN AND RECOMBINANT INTERFERON ALFA-2A IN METASTATIC COLORECTAL-CARCINOMA
    PAZDUR, R
    BREADY, B
    AJANI, JA
    ABBRUZZESE, JL
    MARKOWITZ, A
    SUGARMAN, S
    JONES, D
    LEVIN, B
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (05): : 436 - 438
  • [10] PHASE-II STUDY OF FLUOROURACIL AND RECOMBINANT INTERFERON ALFA-2A IN PREVIOUSLY UNTREATED ADVANCED COLORECTAL-CARCINOMA
    PAZDUR, R
    AJANI, JA
    PATT, YZ
    WINN, R
    JACKSON, D
    SHEPARD, B
    DUBROW, R
    CAMPOS, L
    QUARAISHI, M
    FAINTUCH, J
    ABBRUZZESE, JL
    GUTTERMAN, J
    LEVIN, B
    JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) : 2027 - 2031
12345